Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eldecalcitol

            Therapeutic Area: Musculoskeletal Product Name: Edirol

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Chugai Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination January 22, 2021

            Details:

            Chugai Pharmaceutical and Taisho Pharmaceutical announced termination of the agreement between both companies regarding co-marketing of Edirol® Capsules 0.5 µg and 0.75 µg, a treatment for osteoporosis for which Chugai has a marketing authorization.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eldecalcitol

            Therapeutic Area: Musculoskeletal Product Name: Edirol

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 18, 2020

            Details:

            Chugai has obtained regulatory approval for eldecalcitol (product name: Edirol®), an active vitamin D3 derivative created by Chugai from the China National Medical Products Administration (NMPA).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Polysulfated glycosaminoglycan

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: American Regent

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition April 01, 2020

            Details:

            The facility, previously owned by Daiichi Sankyo Europe, an affiliate of American Regent, produces the API for Adequan®i.m. and Adequan® Canine.